BioVie Inc. (NASDAQ:BIVI) shares traded 54.50% higher at $9.10 on Wall Street last session.
In accordance with the data, 4 analysts cover BioVie Inc. (NASDAQ:BIVI). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $12.00 and a low of $7.00, we find $10.00. Given the previous closing price of $5.89, this indicates a potential upside of 69.78 percent. BIVI stock price is now 115.12% away from the 50-day moving average and 185.27% away from the 200-day moving average. The market capitalization of the company currently stands at $407.41M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
It has been rated a hold by 0 analysts and a buy by 4. Brokers who have rated the stock have averaged $9.75 as their price target over the next twelve months.
With the price target of $7, Cantor Fitzgerald recently initiated with Overweight rating for BioVie Inc. (NASDAQ: BIVI). On January 15, 2021, B. Riley Securities recently initiated its ‘Buy’ rating on the stock quoting a target price of $47.
Insiders disposed of 1,000 shares of company stock worth roughly $9100.0 over the past 1 year. A total of 76.95% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BIVI stock. A new stake in BioVie Inc. shares was purchased by PURA VIDA INVESTMENTS, LLC during the first quarter worth $333,000. HRT FINANCIAL LP invested $160,000 in shares of BIVI during the first quarter. In the first quarter, LPL FINANCIAL LLC acquired a new stake in BioVie Inc. valued at approximately $91,000. In total, there are 20 active investors with 2.10% ownership of the company’s stock.
BioVie Inc. (NASDAQ: BIVI) opened at $6.15 on Thursday. During the past 12 months, BioVie Inc. has had a low of $1.33 and a high of $8.26. As of last week, the company has a debt-to-equity ratio of 2.12, a current ratio of 5.30, and a quick ratio of 5.30. The fifty day moving average price for BIVI is $4.23 and a two-hundred day moving average price translates $3.19 for the stock.
The latest earnings results from BioVie Inc. (NASDAQ: BIVI) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.33, beating analysts’ expectations of -$0.37 by 0.04. This compares to -$0.23 EPS in the same period last year. The company reported revenue of $8.83 million for the quarter, compared to $5.55 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 59.26 percent.
BioVie Inc.(BIVI) Company Profile
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease, as well as Phase 2 clinical trial for the treatment of Parkinson’s disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
